VALIDATION OF HMGI-C AS A DRUG TARGET IN OBESITY

HMGI-C 作为肥胖症药物靶点的验证

基本信息

  • 批准号:
    6381167
  • 负责人:
  • 金额:
    $ 36.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-08-15 至 2003-07-31
  • 项目状态:
    已结题

项目摘要

The unique, novel approach of HMGene to obesity treatment is to develop drugs that act directly on adipose tissue. The goal of Phase II will be to further validate HMGI-C, an architectural transcription factor which regulates gene expression in adipogenesis, as a drug target in obesity. In Phase I, it was shown that inactivation of HMGI-C reverses the obesity induced by leptin deficiency. Phase II will extend those studies to show that the same holds true for diet induced obesity which is a more physiological model and more closely parallels the human disease. As HMGI-C is a transcriptional regulator and sits at the apex of a genomic cascade, DNA microarray and RNA differential display technology will be used to identify genes in the HMGI-C genomic pathway which will provide novel drug targets. Finally, as the ultimate goal is to develop a safe, effective therapeutic for the treatment of obesity, both biochemical and cellular based assays will be developed in order to screen for small molecule inhibitors of HMGI-C which may be useful in the treatment of obesity. PROPOSED COMMERCIAL APPLICATIONS: Successful completion of this project would open up new prospects of the discovery of effective, clinically valuable anti-obesity drugs, which would have an enormous commercial potential. It is estimated that the U.S. mark for a prescription anti-obesity drug is approximately $ 1 billion in annual sales. For an over-the-counter drug, potential market is believed to be $10 billion.
HMGene独特的、新颖的方法是开发直接作用于脂肪组织的药物。II期的目标是进一步验证hgi - c,一种调节脂肪形成基因表达的建筑转录因子,作为肥胖的药物靶点。I期研究表明,hgi - c失活可逆转瘦素缺乏引起的肥胖。第二阶段将扩展这些研究,以证明饮食引起的肥胖同样适用,这是一种更生理的模型,更接近于人类疾病。由于HMGI-C是一种转录调节因子,位于基因组级联的顶端,DNA微阵列和RNA差异显示技术将用于识别HMGI-C基因组通路中的基因,从而提供新的药物靶点。最后,由于最终目标是开发一种安全有效的治疗肥胖的方法,因此将开发生化和基于细胞的检测方法,以筛选可能用于治疗肥胖的HMGI-C的小分子抑制剂。建议的商业应用:本项目的成功完成将为发现有效的、具有临床价值的抗肥胖药物开辟新的前景,这将具有巨大的商业潜力。据估计,美国处方抗肥胖药物的年销售额约为10亿美元。对于非处方药来说,潜在市场被认为是100亿美元。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROLAND A CHOUINARD其他文献

ROLAND A CHOUINARD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROLAND A CHOUINARD', 18)}}的其他基金

Validation of HMGI-C as a Drug Target in Colon Cancer
HMGI-C 作为结肠癌药物靶点的验证
  • 批准号:
    6551961
  • 财政年份:
    2002
  • 资助金额:
    $ 36.18万
  • 项目类别:
VALIDATION OF HMGI C AS A DRUG TARGET IN OBESITY
HMGI C 作为肥胖症药物靶标的验证
  • 批准号:
    2647970
  • 财政年份:
    1999
  • 资助金额:
    $ 36.18万
  • 项目类别:
VALIDATION OF HMGI-C AS A DRUG TARGET IN OBESITY
HMGI-C 作为肥胖症药物靶点的验证
  • 批准号:
    6143070
  • 财政年份:
    1999
  • 资助金额:
    $ 36.18万
  • 项目类别:

相似海外基金

Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
  • 批准号:
    MR/Y013891/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
  • 批准号:
    BB/Y006542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
  • 批准号:
    23H03323
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
  • 批准号:
    23K08293
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
  • 批准号:
    479570
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
  • 批准号:
    488898
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
  • 批准号:
    23K19922
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
  • 批准号:
    10605981
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 36.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了